Breaking News
May 26, 2018 - CRISPR-Cas9-based strategy allows researchers to precisely alter hundreds of different genes
May 26, 2018 - UT Southwestern-led researchers find new way to determine prognosis of invasive kidney cancer
May 26, 2018 - Researchers develop film to prevent bacteria from growing on dental retainers and aligners
May 26, 2018 - Mobile health intervention for people with serious mental illness as effective as clinic-based treatment
May 26, 2018 - Vaginal estradiol tablets outperform moisturizers when treating vulvovaginal problems
May 26, 2018 - Researchers call for new genetic tests for congenital diseases
May 26, 2018 - KHN’s ‘What the Health?’ Campaign promises kept, plus ‘nerd reports’
May 26, 2018 - Lung-on-a-chip technology could streamline drug-testing for pulmonary fibrosis
May 26, 2018 - Study finds early antibiotic initiation for majority of premature infants
May 26, 2018 - New environmental monitoring project finds increased numbers of deer ticks in Southern Indiana
May 26, 2018 - Pediatricians Should Advocate for Life Support Training
May 26, 2018 - Cannabidiol significantly reduces seizures in patients with severe form of epilepsy
May 26, 2018 - Allergies can have serious, far-reaching consequences on adolescents
May 26, 2018 - Scientists develop lab-based system to study mechanisms of common liver disease
May 25, 2018 - New guidelines may help pathologists to more accurately classify and diagnose invasive melanoma
May 25, 2018 - Immune cells promote lung cancer metastases by forming clots in tumors, study finds
May 25, 2018 - Can Excess Weight in Toddlers Cause Brain Drain?
May 25, 2018 - Studying insight
May 25, 2018 - Researchers reveal potent new mechanism of action for treatment of IBD
May 25, 2018 - Study shows lack of follow-up care for patients with concussion
May 25, 2018 - Study establishes the importance of haploid cells
May 25, 2018 - Coveted BMJ award bestowed on The Clatterbridge Cancer Center
May 25, 2018 - AACN outlines evidence-based protocols and clinical strategies to manage alarms
May 25, 2018 - Origami inspires researchers to develop new solution for tissue regeneration
May 25, 2018 - Melorheostosis – Genetics Home Reference
May 25, 2018 - Non-addictive pain medication changing therapy for substance use disorders
May 25, 2018 - Delayed lactate measurements in sepsis patients increase risk of in-hospital death
May 25, 2018 - Researchers identify novel epigenetic mutations as cause of neurodevelopmental, congenital disorders
May 25, 2018 - UD researchers examine connection between DNA replication in HPV and cancer
May 25, 2018 - Researchers identify neurons that play key role in aggressive behavior
May 25, 2018 - Snail’s eye inspires new type of RIOCATH urinary catheter
May 25, 2018 - Russian researchers develop high-tech device-transformer for ultrasound examination
May 25, 2018 - Researchers discover unexpected chemosensor pathway for predator odor-evoked innate fear behaviors
May 25, 2018 - Researchers build 3-D printer that offers sweet solution to making detailed structures
May 25, 2018 - Nearly one in three people know someone addicted to opioids
May 25, 2018 - Research suggests link between faulty gene, alcohol, and heart failure
May 25, 2018 - New findings could help fine-tune treatment for cancer patients
May 25, 2018 - New cancer treatment approach targets specific sugar receptors
May 25, 2018 - Skin responsible for uptake of cancer-causing compounds during barbecuing than lungs
May 25, 2018 - Early-onset cannabis use linked to further drug abuse problems
May 25, 2018 - Covered California takes aim at hospital C-section rates
May 25, 2018 - FDA Approves Palynziq (pegvaliase-pqpz) for the Treatment of Adults with Phenylketonuria
May 25, 2018 - Arthritis Glossary
May 25, 2018 - Study links breast cancer to the body’s internal clock
May 25, 2018 - Strenuous exercise in teenage years may protect against height loss later in life
May 25, 2018 - FDA approves novel enzyme therapy for adults with rare and serious genetic disease
May 25, 2018 - New research project aims at developing effective interventions for kids with DLD
May 25, 2018 - Middlemen who save $$ on medicines — but maybe not for you
May 25, 2018 - Study sheds new light on sharp rise in fatal drug overdoses in recent years
May 25, 2018 - Students propose revision of listeriosis guidelines for safer pregnancy
May 25, 2018 - TNFi Exposure In Utero Does Not Up Serious Infection Risk
May 25, 2018 - Organization of cells in the inner ear enables the sense and sensitivity of hearing
May 25, 2018 - Yoga May Be Right Move Against Urinary Incontinence
May 25, 2018 - Drinking recommended amount of milk could protect obese children against metabolic syndrome
May 25, 2018 - New cytokine network can repair tissue damage in the intestine, study finds
May 25, 2018 - Lyme disease researcher dispels misconceptions about ticks and provides prevention tips
May 25, 2018 - Penn researchers find link between social media usage and underage drinking
May 25, 2018 - Unique nanotechnology method to simplify skin disease diagnosis
May 25, 2018 - Study reveals new protective mechanism for tumor cells in breast cancer
May 25, 2018 - FRAME Alternatives Laboratory chosen for major European liver research collaboration
May 25, 2018 - Study shows yogurt may dampen chronic inflammation linked to multiple diseases
May 25, 2018 - Invasive cancers that are born to be bad show detectable differences from harmless tumors
May 25, 2018 - Study identifies new mechanism involved in development of Lou Gehrig’s disease
May 25, 2018 - UAB professor receives award for malaria prevention study in pregnant women in Cameroon
May 25, 2018 - Study provides blueprint of how fruit flies can be used to screen potentially pathogenic human genes
May 25, 2018 - New drug-delivering nanoparticle could offer better way to treat brain tumors
May 25, 2018 - Kessler Foundation scientists compare two tests for assessing learning in individuals with MS
May 25, 2018 - Stroke Symptoms and Diagnosis (Beyond the Basics)
May 25, 2018 - Protein goes against the family to prevent cancer
May 25, 2018 - Drugmakers blamed for blocking generics have milked prices and cost U.S. billions
May 25, 2018 - Speakers announced for National Medicines Symposium 2018
May 25, 2018 - GSK Receives FDA Approval of Arnuity Ellipta for Asthma in Children From 5 Years of Age
May 25, 2018 - Pfizer settles kickback case related to copay assistance for $24m
May 25, 2018 - Nuclear pore functions are essential for T cell survival
May 25, 2018 - Study defines molecular basis to explain connection between mother’s nutrition and infant growth
May 24, 2018 - IHI hosts representatives to develop a national action plan for patient safety
May 24, 2018 - Zika detection breakthrough by University of Queensland
May 24, 2018 - FDA Alert: 95% Ethyl Alcohol Product by Ethanol Extraction: Recall
May 24, 2018 - New method allows scientists to study how HIV persists
May 24, 2018 - Study reveals rate of vertebral and non-vertebral fractures in children with leukemia
Bortezomib No Help for Kidney Transplant Rejection

Bortezomib No Help for Kidney Transplant Rejection

image_pdfDownload PDFimage_print

Action Points

  • Note that this small randomized trial found no evidence that the anti-plasma cell agent bortezomib is efficacious at reducing antibody-mediated rejection in kidney transplant.
  • Given the higher rate of adverse events in the bortezomib group, the future for the agent in this population does not look bright.

The proteasome inhibitor bortezomib (Velcade) failed to counteract late antibody-mediated rejection in kidney transplant patients, researchers reported from a small randomized trial.

In the placebo-controlled clinical study, overall graft survival at 2 years did not differ significantly between treatment arms and, in fact, numerically favored placebo (81% versus 96%; P=0.12). Patient survival also was no better with bortezomib than placebo (90% versus 100%, respectively; P=0.13), said Georg Böhmig, MD, of the Medical University of Vienna in Austria, and colleagues.

The trial’s primary endpoint, the change in estimated glomerular filtration rate (eGFR) over two years, was not significantly different between the treatment and placebo groups. The eGFR slope was -4.7 for the treatment group and -5.2 for placebo (difference 0.5; 95% CI -4.8 to 5.8; P=0.86), Böhmig and colleagues reported online in the Journal of the American Society of Nephrology.

The drug also had no apparent impact on donor-specific antibodies (DSA). Change in DSA at two years was not significantly different between the treatment and placebo groups, although substantial longitudinal variation of DSA in both groups made it difficult to detect a difference, the study authors reported.

Compounding the drug’s failure, overall adverse events were more common with bortezomib (91 versus 64) as were serious adverse events (10 versus 4). Bortezomib was associated with gastrointestinal toxicity, especially nausea and diarrhea. It was also associated with significantly higher grades of anemia, thrombocytopenia, and leukocytopenia, the study found.

“Our trial challenges the results of previous observational studies and argues against a beneficial effect of bortezomib as a treatment for late antibody-mediated rejection,” Böhmig and colleagues said. “The absence of an effect of bortezomib on DSA and disease activity is important because such effects would be expected, considering the known mechanism of action of the drug.”

Bortezomib, which is approved by the FDA for multiple myeloma and mantle cell lymphoma, promotes the apoptosis of plasma cells, they explained. However, “It is possible that the state of the plasma cells in late antibody-mediated rejection differs from that in other disease conditions in ways that render them less susceptible to the action of bortezomib,” they said.

The trial included 44 kidney transplant recipients diagnosed with late antibody-mediated rejection. They were randomized 1:1 to receive two cycles of either bortezomib or placebo at 3-month intervals in double-blinded fashion. Each treatment cycle consisted of bortezomib at 1.3 mg/m2, administered intravenously twice-weekly on days 1, 4, 8, and 11.

For antiviral prophylaxis, bortezomib-treated patients received oral valacyclovir at 500 mg/day for 3 weeks after initiation of each cycle. Patients in the control group received a 0.9% sodium chloride solution placebo, and instead of valacyclovir they received gelatin capsules filled with maltodextrin. Trial participants were followed for 24 months.

Despite the lack of efficacy reported in this trial, researchers should continue to explore the use of proteasome inhibitors to treat late antibody-mediated rejection of kidney transplants, Böhmig and colleagues said. “An interesting strategy to achieve a longer duration of inhibition and enhanced plasma cell depletion may be the use of new irreversible proteasome inhibitors, such as carfilzomib,” they said.

In addition, bortezomib may be more effective if combined with other agents or treatments, they suggested. “In this respect, the results of an ongoing trial designed to evaluate the effect of bortezomib as part of combinatorial treatment in late antibody-mediated rejection will be of interest,” they said. The Bortezomib in Rejection of Kidney Transplants (TRIBUTE) trial will assess the efficacy of bortezomib in combination with steroids, plasma exchange, and polyclonal intravenous immunoglobulins, according to clinicaltrials.gov.

Böhmig and colleagues noted some limitations to their trial, including using eGFR decline, the study’s main endpoint, as a surrogate of graft survival. However, “A study design to detect meaningful differences in survival rates would have necessitated a long-term multi-center trial including hundreds of patients. Even for our comparatively small trial, screening of more than 700 recipients was necessary for recruitment of less than 50 subjects eligible for the interventional part of the study,” they said.

The study was funded by the Austrian Science Fund and Sandoz GmbH, Austria.

No study authors reported relevant financial relationships.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles